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Abstract
 
Tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) is expressed by in vitro acti-
vated natural killer (NK) cells, but the relevance of this observation to the biological function of
NK cells has been unclear. Herein, we have demonstrated the in vivo induction of mouse
TRAIL expression on various tissue NK cells and correlated NK cell activation with TRAIL-
mediated antimetastatic function in vivo. Expression of TRAIL was only constitutive on a sub-
set of liver NK cells, and innate NK cell control of Renca carcinoma hepatic metastases in the
liver was partially TRAIL dependent. Administration of therapeutic doses of interleukin (IL)-12,
 
a powerful inducer of interferon (IFN)-
 
g
 
 production by NK cells and NKT cells, upregulated
TRAIL expression on liver, spleen, and lung NK cells, and IL-12 suppressed metastases in both
liver and lung in a TRAIL-dependent fashion. By contrast, 
 
a
 
-galactosylceramide (
 
a
 
-GalCer), a
powerful inducer of NKT cell IFN-
 
g
 
 and IL-4 secretion, suppressed both liver and lung me-
tastases but only stimulated NK cell TRAIL-mediated function in the liver. TRAIL expression
was not detected on NK cells from IFN-
 
g
 
–deficient mice and TRAIL-mediated antimetastatic
effects of IL-12 and 
 
a
 
-GalCer were strictly IFN-
 
g
 
 dependent. These results indicated that
TRAIL induction on NK cells plays a critical role in IFN-
 
g
 
–mediated antimetastatic effects of
IL-12 and 
 
a
 
-GalCer.
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Introduction
 
Members of the TNF family of cytokines and receptors are
critically involved in cellular activation, proliferation and
 
death (1, 2). Within this family, TNF, lymphotoxin-
 
a
 
(LT-
 
a
 
), Fas ligand (FasL; reference 1), Apo3L (3), and
 
TNF-related apoptosis-inducing ligand (TRAIL
 
1
 
 [4]) have
been characterized as major mediators of apoptosis in vitro.
TRAIL is a characteristic type II transmembrane protein,
sharing homology with FasL in the extracellular receptor–
binding motif (4). Like FasL, TRAIL induces apoptosis in
tumor cells and virus-infected cells either in vitro or in vivo
(4–7). Unlike other TNF family ligands such as TNF and
FasL, TRAIL does not kill cells from most normal primary
 
tissues
 
 
 
(4, 8). These properties have seen TRAIL pursued
as an anticancer therapeutic itself or in combination with
chemotherapeutic drugs (9–11). Despite current pursuit of
TRAIL as a selective anticancer therapeutic, little is known
of the natural physiological role of TRAIL.
Although TRAIL mRNA has been observed in various
cell types (4, 12), TRAIL protein expression in vivo has
been comparatively poorly defined. TRAIL expression was
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characterized on IFN-
 
a
 
–stimulated peripheral blood T
cells (13) and IFN-stimulated human monocytes and den-
dritic cells (14, 15). TRAIL has also been demonstrated on
CD3
 
2
 
NK1.1
 
1
 
 NK cells after stimulation with IL-2, IFNs,
or IL-15 (16, 17). TRAIL-expressing CD4
 
1
 
 T cells and
mouse NK cells were capable of mediating apoptosis in a
TRAIL-specific fashion (17, 18). These preliminary find-
ings suggested that TRAIL may play a role in innate im-
mune responses involving IFN and NK cells. We have es-
tablished several mouse spontaneous and metastatic tumor
models in which NK cells use the cytotoxic granule pro-
tein, perforin (pfp), to control tumor initiation and me-
tastasis (19, 20). More recently, we have shown that IFN-
 
g
 
secretion independently contributes to the natural NK cell
response (21) or the NK cell response activated by biologi-
cal response modifiers such as IL-12 (22). Therefore, we ra-
tionalized that TRAIL may contribute to NK cell–medi-
ated antitumor responses that are IFN-
 
g
 
 dependent. In this
study, we observed that potent inducers of IFN-
 
g
 
 and NK
cell effector function partially mediate their antitumor ac-
tivity by stimulating TRAIL expression on NK cells.
 
Materials and Methods
 
Mice.
 
Inbred BALB/c wild-type (WT) mice were purchased
from The Walter and Eliza Hall Institute of Medical Research
and Clear Japan Inc. The following gene-targeted mice were
bred at the Peter MacCallum Cancer Institute: BALB/c pfp defi-
cient (BALB/c pfp
 
2
 
/
 
2
 
; reference 23), BALB/c IFN-
 
g
 
 deficient
(BALB/c IFN-
 
g
 
2
 
/
 
2
 
; reference 24), and BALB/c CD1d deficient
(BALB/c CD1d
 
2
 
/
 
2
 
; provided by Dr. L. Van Kaer, Vanderbilt
University School of Medicine, Nashville, TN). Mice of 6–10
wk of age were used in all experiments that were performed ac-
cording to animal experimental ethics committee guidelines.
 
Tumor Cells and Reagents.
 
The BALB/c-derived renal adeno-
carcinoma cell line, Renca (H-2
 
d
 
), was provided by Dr. T. Sayers
(National Cancer Institute-Frederick Cancer Research and De-
velopment Center) and maintained in RPMI 1640 containing
10% FCS and 2 mM 
 
l
 
-glutamine. Recombinant mouse IL-12
and IL-2 was provided by Genetics Institute (Andover, MA) and
Chiron Corp. (Emeryville, CA), respectively. Recombinant
mouse IFN-
 
g
 
 was purchased from BD PharMingen. The prepa-
rations of IL-12 and IL-2 were diluted in PBS immediately before
use. 
 
a
 
-galactosylceramide (
 
a
 
-GalCer) was provided by the Phar-
maceutical Research laboratories, Kirin Brewery (Gumna, Japan),
and prepared as described (25). 
 
a
 
-GalCer was suspended in saline
supplemented with 0.5% polysorbate-20 (wt/vol) and the control
vehicle was saline supplemented with 0.5% polysorbate-20 (wt/
vol). Concanamycin A (CMA), which inhibits pfp-mediated cy-
totoxicity (17), was purchased from Wako Pure Chemicals.
 
Flow Cytometric Analysis.
 
Mononuclear cells (MNCs) were
prepared from the spleen, liver, lung, and peripheral blood as de-
scribed previously (26, 27). To avoid the nonspecific binding of
Abs to Fc
 
g
 
R, the cells were preincubated with anti–mouse
CD16/32 (2.4G2) mAb before staining. The cells were then in-
cubated with a saturating amount (1 
 
m
 
g) of biotinylated anti–
mouse TRAIL (N2B2) mAb (17) before incubation with a satu-
rating amount of PE-conjugated streptavidin, FITC-conjugated
anti–mouse NK cell (DX5) mAb, and Cy-Chrome–conjugated
anti-CD3 (145-2C11) mAb. All these reagents, except anti–
mouse TRAIL mAb, were obtained from BD PharMingen. After
 
washing with PBS twice, the stained cells were analyzed on a
FACScan™ (Becton Dickinson) and the data were processed by
the CELLQuest™ program (Becton Dickinson).
 
Cytotoxicity and Serum IFN-
 
g
 
 Assays.
 
Cytotoxic activities of
hepatic, spleen, and lung MNCs were tested against Renca cells
by an 8 h 
 
51
 
Cr-release assay as described previously (13, 17). In
some experiments, the assay was performed in the presence of
anti-TRAIL (N2B2) mAb (10 
 
m
 
g/ml), control Ig (rat IgG2a,
R35-95; 10 
 
m
 
g/ml; BD PharMingen), and/or CMA (50 nM).
Serum was collected from various treated mice as indicated and
measured by a mouse IFN-
 
g
 
–specific ELISA according to the
manufacturer’s protocol (BD PharMingen).
 
Experimental Metastasis Assay.
 
BALB/c WT and gene-tar-
geted mice were injected intrasplenically or intravenously with
Renca tumor cells as described previously (28). Mice were killed
14 d after tumor inoculation and liver (after intrasplenic) or lung
(after intravenous) metastases were quantified with the aid of a
dissecting microscope. Some mice received either anti–mouse
TRAIL mAb (250 
 
m
 
g intraperitoneally) or control rat IgG2a
(R35–95; 250 
 
m
 
g/ml intraperitoneally) on days 0, 1, and 7 after
tumor inoculation. Some groups of mice were additionally de-
pleted of NK cells in vivo by treatment with 20 
 
m
 
g polyclonal
rabbit anti-asialoGM1 (anti-asGM1) Ab (Wako) on days 
 
2
 
1, 0,
and 7 relative to tumor inoculation. This depletion protocol has
been shown to selectively deplete NK cells, but not other leuko-
cyte subsets including NKT cells, in both C57BL/6 and BALB/c
mouse strains (21). Anti-TRAIL mAb did not deplete NK cells in
any organ examined (data not shown). Antimetastatic treatment
protocols were as follows: IL-2, 100,000 U/200 
 
m
 
l PBS intra-
peritoneally daily on days 3 through 7 (where day 0 was the day of
tumor inoculation); IL-12, 500 U/200 
 
m
 
l PBS intraperitoneally
daily on days 3 through 7; and 
 
a
 
-GalCer, 2 
 
m
 
g/200 
 
m
 
l PBS intra-
peritoneally on days 0, 4, and 8. These regimes were chosen based
on previous efficacy studies of these immunotherapies in Renca
and other tumor models (22, 27, 28, and data not shown).
 
Results
 
IL-12 and 
 
a
 
-GalCer Specifically Induce TRAIL In Vivo.
 
IL-2 (29), IL-12 (30–32), and 
 
a
 
-GalCer (25, 33, 34) have
been shown to induce proliferation, IFN-
 
g
 
 production and
cytotoxicity of NK cells in vivo, which are associated with
their antitumor effects. Regimes of treatments using IL-2,
IL-12, or 
 
a
 
-GalCer alone were designed based on their ef-
ficacy against Renca tumor metastases. The MNCs in each
of liver, spleen, lung, and peripheral blood (PBMC) were
analyzed 24 h after the final treatment for DX5 and CD3
expression (Fig. 1 A). Two- to threefold more cells were
present in the livers and spleens of treated mice compared
with control treated mice (data not shown). TRAIL ex-
pression has not previously been characterized on lympho-
cyte populations stimulated with these biological response
modifiers. A low level of constitutive TRAIL expression
was found on freshly isolated liver CD3
 
2
 
DX-5
 
1
 
 NK cells,
but not CD3
 
1
 
DX-5
 
2
 
 T cells, CD3
 
1
 
DX-5
 
1
 
 T cells, or
CD3
 
2
 
DX-5
 
2
 
 cells including B cells and macrophages from
the liver of untreated BALB/c mice (Fig. 1 B, control).
NK cells freshly isolated from the spleen, lung, and periph-
eral blood (Fig. 1 B, control) did not express TRAIL. Ad-
ministration of IL-12 (500 U intraperitoneally for 5 d) se-
lectively upregulated TRAIL expression on NK cells in the 
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liver and also induced TRAIL expression on spleen and
lung NK cells (Fig. 1 B). A single injection of 500 U IL-12
was sufficient to induce expression of TRAIL on NK cells,
but expression was comparatively low. Single or repeated
IL-12 injections did not induce TRAIL on DX-5
 
1
 
 T cells
(data not shown). Administration of 
 
a
 
-GalCer (2 
 
m
 
g intra-
peritoneally for days 0, 4, and 8) also upregulated TRAIL
on liver NK cells (on day 9) and induced TRAIL on spleen
NK cells, but not on lung NK cells (Fig. 1 B). A single in-
jection of 2 
 
m
 
g 
 
a
 
-GalCer did not induce detectable
TRAIL expression on NK cells until 48 h later, but TRAIL
expression remained significant for at least 4 d. TRAIL
expression was never detected on lung NK
 
 
 
cells or any
DX-5
 
1
 
 T cells (BALB/c) or NK1.1
 
1
 
 T cells (C57BL/6; 3,
6, 24, 72, or 96 h) after 
 
a
 
-GalCer treatment (data not
shown). Administration of IL-2 (100,000 U intraperito-
neally for 5 d) induced NK cell proliferation (data not
shown), but did not induce TRAIL expression on NK cells
or T cells in any organs examined (Fig. 1 B). TRAIL was
never induced on NK cells after IL-2 administration. These
results indicated that IL-12 and 
 
a
 
-GalCer selectively in-
duce TRAIL expression on NK cells in vivo.
 
IL-12 and 
 
a
 
-GalCer Induce TRAIL-mediated Cytotox-
icity.
 
To evaluate the contribution of TRAIL to the cyto-
toxicity of hepatic, splenic, and lung NK cells after the ad-
ministration of IL-12
 
, 
 
a
 
-GalCer, or IL-2, the effect of
neutralizing anti-TRAIL mAb was examined in a cytotox-
icity assay using liver, spleen, or lung MNCs as the effector
and TRAIL-sensitive Renca tumor cells as the target. The
cytotoxicity of liver MNCs from untreated control mice
was inhibited partially by anti-TRAIL mAb alone and
completely by the combination with a pfp inhibitor CMA
(Fig. 2, left). Administration of IL-12, 
 
a
 
-GalCer, or IL-2
markedly augmented the cytotoxicity of liver MNCs,
which was also inhibited partially by anti-TRAIL mAb
alone and completely by combination with CMA. The cy-
totoxicity of spleen MNCs from untreated or IL-2–treated
mice was completely abrogated by CMA, whereas that
Figure 1. IL-12 and a-GalCer induce TRAIL ex-
pression on NK cells. MNCs from the liver, spleen,
lung, and peripheral blood (PBMC) were isolated from
PBS or vehicle-treated (control) BALB/c mice or IL-
12 (500 U intraperitoneally on days 25, 24, 23, 22,
and 21), a-GalCer (a-GC; 2 mg intraperitoneally on
days –8, 24, and 0), or IL-2 (100,000 U intraperito-
neally on days 25,  24,  23,  22, and 21)–treated
BALB/c mice at 24 h after the treatment. These cells
were stained with biotin-conjugated anti-TRAIL mAb
followed by PE-conjugated streptavidin, FITC-conju-
gated anti-DX5 mAb, and Cy-Chrome–conjugated
anti-CD3 mAb. (A)  DX5 (y-axis) vs. CD3 (x-axis)
staining profiles of MNCs from each organ after the in-
dicated treatments. Percentages of DX51CD32 cells
and DX51CD31 cells are indicated at the top left and
top right, respectively. Two- to threefold more cells
were present in the livers and spleens of IL-12–, a-Gal
Cer–, or IL-2–treated mice. (B) Expression of TRAIL
was analyzed on electronically gated CD32DX-51
(NK) cells, CD31DX-52 (T) cells, CD31DX-51
T cells, and CD32DX-52 (DN) cells by flow cytome-
try. Bold lines indicate staining with anti-TRAIL mAb
and plain lines indicate staining with isotype-matched
control IgG2a. These analyses (A and B) have been
performed on more than three occasions and these pro-
files are representative.664 IFN-g–dependent TRAIL Tumor Suppressor Function
from IL-12– or a-GalCer–treated mice was inhibited par-
tially by anti-TRAIL mAb alone and completely by the
combination with CMA (Fig. 2, middle). The cytotoxicity
of lung MNCs from untreated, a-GalCer–treated, or IL-2–
treated mice was abrogated by CMA alone, whereas that
from IL-12–treated mice was inhibited partially by anti-
TRAIL mAb alone and completely by the combination
with CMA (Fig. 3, right). All these partial contributions of
TRAIL to the cytotoxicity were totally consistent with the
TRAIL expression on liver NK cells, spleen NK cells after
IL-12 or a-GalCer treatment, and lung NK cells after IL-
12 treatment shown in Fig. 1.
Involvement of TRAIL in Antimetastatic Effects of IL-12 and
a-GalCer. IL-2, IL-12, and a-GalCer have been demon-
strated to possess potent antimetastatic activity when ad-
ministered to mice (22, 26–28, 35–37). In particular, IL-2
and IL-12 have previously been shown to substantially re-
duce Renca tumor cell metastasis in BALB/c mice (28).
Varying doses of Renca cells were inoculated intraspleni-
cally, and at the lower tumor doses administered, anti-
TRAIL mAb significantly increased liver metastases,
whereas isotype control IgG where tested was without ef-
fect (Fig. 3 A). This data was consistent with constitutive
expression of cytotoxic TRAIL on liver NK cells (Fig. 1
B). A minimum inoculum of 3 3 105 Renca tumor cells
that metastasized equivalently in untreated or anti-TRAIL–
treated WT mice was used for subsequent immunotherapy
experiments. After intrasplenic inoculation of 3 3 105
Renca cells, therapeutic administration of IL-2, IL-12, or
a-GalCer significantly reduced numbers of Renca liver
metastases (Fig. 3 B). These antimetastatic activities were
completely abolished by anti-asGM1 Ab, indicating that all
these modifiers mediated their activities via NK cell effec-
tor function. In concert with increased cytotoxicity by acti-
vated liver MNCs (Fig. 2), the neutralizing anti-TRAIL
mAb significantly increased the number of Renca liver me-
tastases in IL-12– or a-GalCer–treated mice (Fig. 3). By
contrast, anti-TRAIL mAb only marginally reduced the
antimetastatic activity of IL-2 (Fig. 3). These data indicated
Figure 2. IL-12 and a-GalCer induce TRAIL-
mediated cytotoxicity. Liver, spleen, and lung
MNCs were isolated (day 0) from PBS or vehicle-
treated (control) BALB/c mice or IL-12 (500 U in-
traperitoneally on days 25, 24, 23, 22, and 21),
a-GalCer (a-GC; 2 mg intraperitoneally on days
28, 24, and 0), or IL-2 (100,000 U intraperito-
neally on days 25, 24, 23, 22, and 21)–treated
BALB/c mice at 24 h after the treatment. Their cy-
totoxic activities were tested against TRAIL-sensi-
tive Renca tumor cells in the presence or absence of
50 nM CMA, 10 mg/ml of anti-TRAIL mAb, or 10
mg/ml of control rat IgG2a mAb (control IgG) by
8 h 51Cr-release assay at several effector/target ratios
(100:1 spleen MNCs, 50:1 liver and lung MNCs,
shown). Data are represented as the mean 6 SD of
triplicate samples. Similar results were obtained in
three independent experiments. *P , 0.05, com-
pared with control IgG by two sample t tests.
Figure 3. The antimetastatic activity of IL-12– or a-GalCer–activated
liver NK cells involves TRAIL effector function. Groups of 5 to 20 WT
mice were inoculated intrasplenically with (A) between 1 3 104 and 3 3
105 Renca tumor cells or (B) 3 3 105 Renca tumor cells on day 0. As in-
dicated, some groups of mice were treated with one or more of: 500 U
IL-12 intraperitoneally on days 3 through 7; 100,000 U IL-2 intraperito-
neally on days 3 through 7; 2 mg a-GalCer (a-GC) intraperitoneally on
days 0, 4, and 8; 20 mg anti-asGM1 on days 21, 0, and 7; and 0.25 mg
anti-TRAIL mAb or control IgG intraperitoneally on days 0, 1, and 7.
The livers were removed from mice on day 14, and the metastatic nod-
ules quantified. Data are recorded as the mean 6 SE, with the significance
of anti-TRAIL mAb-treated mice compared with untreated or control
IgG-treated mice as defined by Mann Whitney U test, *P , 0.05, **P ,
0.01. IL-12, a-GalCer, and IL-2 were also statistically effective alone
compared with no treatment in the livers of WT mice (P , 0.01). There
was no effect of rabbit IgG (control for anti-asGM1) on the efficacy of
a-GalCer, IL-12, or IL-2 (data not shown).665 Smyth et al.
that IL-12– or a-GalCer–, but not IL-2–stimulated antitu-
mor activity in the liver was partially effected by TRAIL.
As constitutive TRAIL expression was not observed on
spleen or lung NK cells, we reasoned that TRAIL function
may not be observed in Renca models of lung metastasis.
Indeed at three Renca doses examined (1 3 104, 5 3 104,
and 1 3 105), anti-TRAIL mAb did not significantly en-
hance Renca lung metastasis (Fig. 4 A). However, after
treatment with IL-12, TRAIL expression was observed on
lung NK cells (Fig. 1 B) and IL-12 significantly reduced the
number of Renca lung metastases (Fig. 4 B). Furthermore,
anti-TRAIL mAb significantly increased Renca lung me-
tastases in IL-12–treated mice, indicating that part of the
antimetastatic activity of IL-12 was mediated by TRAIL
(Fig. 4 B). Lung NK cell TRAIL expression was not in-
duced in a-GalCer–treated mice and no significant antime-
tastatic effect of TRAIL was detected in the lung (Fig. 4 B).
NK cell TRAIL expression and function was not detected
in the lung after an antimetastatic dose of IL-2 (Fig. 4 B).
Key Role of IFN-g in TRAIL-mediated Antimetastatic Effect
of IL-12. Using gene-targeted mice we next examined
the relative role of pfp and IFN-g in the TRAIL-mediated
antimetastatic activity stimulated by IL-12. Consistent with
our previous observations (21), both pfp and IFN-g con-
tributed to NK cell control of Renca tumor metastasis.
IFN-g played a greater relative role than pfp in IL-12–
mediated antimetastatic activity of NK cells in the liver
(Fig. 5 A). In the lung, pfp-mediated protection was more
important (Fig. 5 B). In both liver (Fig. 5 A) and lung (Fig. 5
B) metastasis models, anti-TRAIL mAb enhanced metastasis
in IL-12–treated pfp2/2 but not IFN-g2/2 mice. These data
indicated that TRAIL is a key effector molecule mediating
the IFN-g–dependent antimetastatic effect of IL-12.
Role of IFN-g in Antimetastatic Effect of a-GalCer. Us-
ing pfp2/2 and IFN-g2/2 mice we next examined the in-
volvement of IFN-g and TRAIL in the antimetastatic ac-
tivity stimulated by a-GalCer. In both liver (Fig. 6 A) and
lung (Fig. 6 B) metastasis models, IFN-g was essential for
Figure 4. IL-12 stimulates TRAIL-mediated antimetastatic activity in
the lung. Groups of 5 to 20 WT mice were inoculated intravenously with
(A) between 104 and 105 Renca tumor cells or (B) 105 Renca tumor cells
on day 0. As indicated, some groups of mice were treated with one or
more of: 500 U IL-12 intraperitoneally on days 3 through 7; 100,000 U
IL-2 intraperitoneally on days 3 through 7; 2 mg a-GalCer (a-GC) intra-
peritoneally on days 0, 4, and 8; 20 mg anti-asGM1 on days 21, 0, and 7;
and 0.25 mg anti-TRAIL mAb or control IgG intraperitoneally on days
0, 1, and 7. The lungs were removed from mice on day 14, and the met-
astatic nodules quantified. Data are recorded as the mean 6 SE, with the
significance of anti-TRAIL mAb-treated mice compared with untreated
or control IgG-treated mice as defined by Mann Whitney U test; *P ,
0.05, **P , 0.01. IL-12, a-GalCer, and IL-2 were also statistically effec-
tive alone compared with no treatment in the livers of WT mice (P ,
0.01). There was no effect of rabbit IgG (control for anti-asGM1) on the
efficacy of a-GalCer, IL-12, or IL-2 (data not shown).
Figure 5. Key role of IFN-g in TRAIL-mediated antimetastatic effect
of IL-12. Groups of 5 to 15 IFN-g2/2 or pfp2/2 mice were inoculated
(A) intrasplenically with 3 3 105 Renca tumor cells or (B) intravenously
with 1 3 105 Renca tumor cells on day 0. As indicated, some groups of
mice were treated with: 500 U IL-12 intraperitoneally on days 3 through
7 and/or 0.25 mg anti-TRAIL mAb or control IgG intraperitoneally on
days 0, 1, and 7. The (A) livers and (B) lungs were removed from mice on
day 14, and the metastatic nodules quantified. Data are recorded as the
mean 6 SE, with the significance of anti-TRAIL mAb-treated mice
compared with untreated or control IgG-treated mice as defined by *P ,
0.05, **P , 0.01, Mann-Whitney U test. IL-12 was statistically effective
alone compared with no treatment in the livers and lungs of both pfp2/2
and IFN-g2/2 mice (P , 0.01). Control IgG was without effect in the
experiment shown in B (data not shown).666 IFN-g–dependent TRAIL Tumor Suppressor Function
the a-GalCer activity. By contrast, a-GalCer significantly
reduced Renca metastasis in pfp2/2 mice, in both liver and
lung. Anti-TRAIL mAb only enhanced liver metastasis in
a-GalCer–treated pfp2/2 mice and TRAIL antitumor
function was not detected in the lung after a-GalCer ad-
ministration. In summary, a-GalCer demonstrated IFN-g–
dependent antimetastatic activity in both liver and lung;
however, TRAIL expression (Fig. 1 B) and function was
only demonstrated in the liver.
Correlation between IFN-g Activity and NK Cell TRAIL
Expression. To further demonstrate the relationship be-
tween IFN-g activity and TRAIL expression and function
on NK cells, we characterized the kinetics of serum IFN-g
induction in mice that had received a single or multiple
(regime) doses of IL-12, a-GalCer, or IL-2 (Fig. 7 A). Af-
ter a single dose of IL-12 or a-GalCer a significant induc-
tion of IFN-g was detected in the serum with levels peak-
ing at between 6 to 10 ng/ml. IL-2 also induced serum
IFN-g; however, the levels were more moderate (,3 ng/
ml). The rapid induction of serum IFN-g in response to
a-GalCer was also evident in anti-asGM1–treated mice,
but did not occur in CD1d2/2 mice, indicating the early and
critical role for NKT cells in this response. IL-12–induced
serum IFN-g levels were clearly reduced in both anti-
asGM1–treated WT mice or CD1d2/2 mice, suggesting
that both NK and NKT cells were contributing to IFN-g
production. IL-2–induced serum IFN-g levels were com-
pletely dependent on NK cells. 24 h after the treatment re-
gimes used for therapy of Renca metastases, serum IFN-g
levels were highest in IL-12–treated mice, then a-GalCer–
treated mice and IL-2–treated mice (Fig. 7 B). These data
indicated that appreciable serum IFN-g levels were de-
tected before TRAIL expression on NK cells, and that the
reduced capacity of IL-2 to stimulate and maintain high
IFN-g levels correlated with its inability to induce TRAIL
expression in vivo.
We next examined the ability of IFN-g, IL-12, and a-Gal
Cer to induce NK cell TRAIL expression in BALB/c
IFN-g2/2 mice (Fig. 7 C). Liver and spleen NK cells from
IFN-g2/2 mice did not constitutively express TRAIL;
however, treatment of these mice with IFN-g induced
both liver and spleen NK cell TRAIL expression. By con-
trast, treatment with either IL-12 or a-GalCer did not in-
duce NK cell TRAIL. These data directly supported the
conclusion that IFN-g plays a key role in TRAIL expres-
sion and TRAIL-mediated antimetastatic function of NK
cells.
Discussion
It has long been recognized that NK cell function can be
activated by IFN-g (38) and that IFN-g can contribute to
host antitumor immunity (39, 40). Direct and macrophage-
mediated antitumor activities of IFN-g have been de-
scribed (38), and IFN-g has been shown to sensitize tumor
cells to both pfp- (41) and FasL-mediated apoptosis (42).
However, herein we provide the first evidence that IL-12
and a-GalCer immunotherapies that stimulate IFN-g pro-
duction can recruit the antitumor activity of NK cell
TRAIL. At this stage, it is unknown what relative or gen-
eral contribution NK cell TRAIL makes to the suppression
of tumor metastasis, but under the appropriate activation
conditions NK cell TRAIL can act in the liver and lung.
NK cell TRAIL antitumor function appears to be limited
to TRAIL-sensitive tumors (for example, Renca and 4T1
mammary carcinoma), as the anti-TRAIL mAb has no ef-
fect on immunity against TRAIL-resistant tumors (for ex-
ample, B16 melanoma and 3LL lung carcinoma; our un-
published observations). Although Renca is controlled by
NK cells in these models, it remains possible that other
IFN-g–regulated effector cells may mediate their antitumor
activities via TRAIL. TRAIL with tumoricidal activity has
also been shown to be induced on human monocytes and
dendritic cells in vitro (14, 15); however, we did not detect
significant TRAIL expression on mouse non-NK leuko-
cytes in the organs examined, nor did we observe mono-
cyte/dendritic cell depletion after anti-asGM1 treatment.
The documented involvement of IL-12/IFN-g in the im-
mune surveillance of methylcholanthrene-induced sarcoma
Figure 6. Role of IFN-g and TRAIL in antimetastatic effect of
a-GalCer. Groups of five IFN-g2/2 or pfp2/2 mice were inoculated (A)
intrasplenically with 3 3 105 Renca tumor cells or (B) intravenously with
1 3 105 Renca tumor cells on day 0. As indicated, some groups of mice
were treated with: 2 mg a-GalCer (a-GC) intraperitoneally on days 0, 4,
and 8 and/or 0.25 mg anti-TRAIL mAb on days 0, 1, and 7. The (A) liv-
ers and (B) lungs were removed from mice on day 14, and the metastatic
nodules quantified. Data are recorded as the mean 6 SE, with the signi-
ficance of anti-TRAIL mAb-treated mice compared with mice treated
with a-GalCer alone as defined by *P , 0.05, **P , 0.01, Mann-Whit-
ney U test. Control IgG was without effect in pfp2/2 or IFN-g2/2 mice
(data not shown). a-GalCer was statistically effective alone compared
with no treatment in the livers and lungs of pfp2/2 mice (P , 0.01).667 Smyth et al.
(19) and IFN-g in tumor development in p53 mutant mice
(40) begs the question of whether TRAIL plays a broader
role in tumor surveillance.
The constitutive expression of TRAIL on liver NK cells
raises the issue of what normal physiological role TRAIL
plays in the liver. It is possible that liver NK cells may ex-
press TRAIL in response to gut-derived endogenous en-
dotoxin or in early responses to infections. Infections in the
liver are most often controlled by NK cell secretion of anti-
viral cytokines, rather than by direct cytolysis; however,
hepatocytes have almost undetectable MHC class I mole-
cule expression and thus may represent significant targets
for NK cell–mediated death. Although mouse hepatocytes
are resistant to TRAIL under normal conditions, it is possi-
ble that after activation mouse hepatocytes may also be tar-
gets for TRAIL-mediated cell death. Human TRAIL has
been demonstrated to cause apoptosis of human hepato-
cytes in vitro (43), but this finding remains unsubstantiated
in vivo. Activated lymphocytes clearly cause liver injury in
virus-infected or a-GalCer–treated mice (44, 45), and it
remains to be determined whether TRAIL participates in
this damage. Alternatively, the liver is a site for lymphocyte
cell death (46, 47) and TRAIL may play a natural role in
the surveillance of stressed cells in the liver (48).
Although T cells did not express TRAIL under any cir-
cumstances tested here, an implicit finding from our a-Gal
Cer immunotherapy data is that NKT cells can initiate an
IFN-g–dependent induction of NK cell TRAIL function
in the liver. Stimulation of serum IFN-g by a-GalCer
was rapid and dependent on NKT cells, consistent with
NKT cells providing IFN-g to secondarily activate NK cell
function (49). NKT cells also played a role in IL-12 induc-
tion of IFN-g, and we and others have previously shown
in other tumor models that IL-12 preferentially stimulates
NKT cell activation and IL-12 requires NKT cells for its
antitumor activity (22, 27, 35). Induction of TRAIL on
NK cells via autocrine NK cell IFN-g secretion may also
be important given that TRAIL is constitutively expressed
on liver NK cells of WT, but not IFN-g2/2 mice. The re-
jection of TRAIL-insensitive tumors by a-GalCer also ap-
peared to involve indirect activation of NK cells, as they
too were inhibited by anti-asGM1 Ab (unpublished obser-
vations). Future NKT cell transfer experiments will be re-
quired to definitively show that NKT cells provide IFN-g
to activate NK cell TRAIL expression and function.
Although IFN-g appears critical for effective TRAIL ex-
pression and function, not all inducers of IFN-g activate
NK cell TRAIL expression. Effective doses of IL-2 did not
stimulate NK cell TRAIL expression or function in vivo,
despite inducing moderate levels of serum IFN-g. Previ-
ously, IL-18 did not induce TRAIL expression on murine
NK cells in vitro (17), despite strongly inducing IFN-g
production by NK cells and augmenting pfp- and FasL-
mediated NK cell cytotoxicity (50, 51). None of the stimu-
Figure 7. Correlation between IFN-g activity and NK cell TRAIL expression. (A) Serum was col-
lected from untreated (j) or anti-asGM1–treated BALB/c WT mice (d) or BALB/c CD1d2/2 mice (m)
as indicated, and mouse IFN-g measured by a specific ELISA. (B) Sera were also taken 24 h after treat-
ment as per the Renca tumor therapy regime (above) from IL-12– (black bars), a-GalCer– (white bars),
or IL-2 (striped bars)–treated mice. For A and B, data represent the mean 6 SE (ng/ml) of duplicate sam-
ples from three different mice. The serum of all untreated mice contained ,50 pg/ml of IFN-g. (C)
MNCs from the liver and spleen were isolated from PBS- or vehicle-treated (control) BALB/c IFN-g2/2
mice at 24 h after the treatment with IL-12 (500 U intraperitoneally on days 25, 24, 23, 22, and 21)
or a-GalCer (a-GC; 2 mg intraperitoneally on days 28, 24, and 0), or at 3 h after the treatment with
IFN-g (50,000 U intraperitoneally). These cells were stained with biotin-conjugated anti-TRAIL mAb
followed by PE-conjugated streptavidin, FITC-conjugated anti-DX5 mAb, and Cy-Chrome–conjugated anti-CD3 mAb. Expression of TRAIL was
analyzed on electronically gated CD32DX-51 (NK) cells by flow cytometry. Bold lines indicate staining with anti-TRAIL mAb and plain lines indicate
staining with isotype-matched control IgG2a.668 IFN-g–dependent TRAIL Tumor Suppressor Function
lators of serum IFN-g–induced TRAIL expression on
PBMC NK cells, suggesting that proximity between NKT
cells and NK cells may be required. It was also curious that
a-GalCer induced TRAIL expression on spleen NK cells,
but not lung NK cells, despite the fact that IL-12 induced
TRAIL on both populations of NK cells. There are fewer
NKT cells in the lungs and the NKT cell/CD1d–a-GalCer
interaction may not be efficient in the lung. In addition,
IL-12 directly stimulates NK cell IFN-g production and
therefore NK cell TRAIL expression may not require indi-
rect activation by lung NKT cells. Thus, although it is pos-
sible that continuous IFN-g production in the environ-
ment of the NK cell is important for TRAIL induction, the
complex issue of what other factors determine TRAIL ex-
pression in different tissues remains unresolved.
It has been recognized in mouse pathogen models that
the immune effector response is controlled in a compart-
ment-specific manner (52). Our data indicate that antitu-
mor effector mechanisms also differ in their relative impor-
tance in the liver and lung. The two major effector
mechanisms used by NK cells in their control of tumor
metastasis are pfp and IFN-g (21). Herein, we have shown
that IFN-g control of metastasis appears particularly impor-
tant in the liver and TRAIL is at least one effector mecha-
nism that acts downstream of IFN-g during effective treat-
ment with IL-12 or a-GalCer.
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